|Ms. Carrie L. Bourdow||Pres, CEO & Director||1.14M||N/A||1963|
|Dr. Mark A. Demitrack||Sr. VP & Chief Medical Officer||725.67k||N/A||1958|
|Dr. Howard A. Rockman M.D.||Scientific Founder, Consultant and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Barry Shin||Sr. VP & CFO||N/A||N/A||1972|
|Mr. Michael Catalano||VP of Marketing||N/A||N/A||N/A|
|Mr. Robert T. Yoder||Sr. VP, Chief Bus. Officer & Head of Commercial Operations||N/A||N/A||1966|
|Ms. Patricia M. Drake||Chief Commercial Officer||N/A||N/A||N/A|
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.